Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

222
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
222
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

784
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
784
Lipid Absorption01:24

Lipid Absorption

595
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
595
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

29
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
29
Lipid Digestion01:06

Lipid Digestion

92.9K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
92.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial.

Atherosclerosis·2026
Same author

The Unpaid Infrastructure of Cardiovascular Science.

JACC. Advances·2026
Same author

Identifying severe hypercholesterolemia in participants of ASCVD trials: Implications for trial conduct and opportunistic screening.

Journal of clinical lipidology·2026
Same author

Impact of Work-Related Stressors on Pregnancy Outcomes of Cardiologists and Cardiovascular Team Members: It Is Complicated.

JACC. Advances·2026
Same author

Gender Matters: A State-of-the-Art Review of Transcatheter Structural Interventions in Older Women Vs Men.

JACC. Advances·2026
Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026
Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026
Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026
Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026
Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026
Same journal

HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?

Current opinion in lipidology·2026
See all related articles

Related Experiment Video

Updated: Aug 22, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K

Recent lipoprotein(a) trials.

Trent Wei1, Leslie Cho

  • 1Department of Preventive Cardiology and Rehabilitation, Women's Cardiovascular Center, Cleveland Clinic, Cleveland, Ohio, USA.

Current Opinion in Lipidology
|November 8, 2022
PubMed
Summary
This summary is machine-generated.

New RNA therapies effectively lower Lipoprotein(a) (Lp(a)) levels, a key genetic risk factor for cardiovascular disease. These novel treatments show promising efficacy and safety in recent clinical trials.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Related Experiment Videos

Last Updated: Aug 22, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pharmacology

Background:

  • Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and calcific aortic stenosis.
  • Serum Lp(a) levels are minimally impacted by conventional lipid-lowering therapies for hypercholesterolemia and hypertriglyceridemia.

Approach:

  • RNA-targeted therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), directly target the LPA gene.
  • These therapies inhibit the hepatic synthesis of apolipoprotein(a), a critical component of Lp(a).
  • Novel drugs such as pelacarsen (ASO), olpasiran (siRNA), and SLN360 (siRNA) have been developed.

Key Points:

  • Pelacarsen, olpasiran, and SLN360 have demonstrated significant efficacy in reducing serum Lp(a) levels.
  • These RNA-based therapies exhibit excellent safety profiles in clinical studies.
  • The development of RNA therapies represents a significant advancement in managing Lp(a)] levels.

Conclusions:

  • RNA-directed therapies offer a potent new strategy for lowering Lp(a) levels.
  • These novel therapeutics show considerable promise for cardiovascular disease risk reduction.
  • Future clinical trials will focus on cardiovascular outcomes data to further establish the benefit of these Lp(a) lowering therapies.